LifeMD (LFMD) Peer Comparison

$3.26

$0.02 (0.62%)

As on 27-Aug-2026 16:00EDT

Market cap

$160 Mln

Revenue (TTM)

$204 Mln

P/E Ratio

--

P/B Ratio

19.9

Div. Yield

0 %

Edit

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	160	12,753	10,906	9,762	10,222
Revenue ($ Mln)	204	1,505	613	2,589	785
Net Profit ($ Mln)	-21.26	160.59	-188.05	222.40	41.54
Net Margin (%)	-10.40	10.67	-30.68	8.59	5.29
RoE (%)	-138.09	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	19.91	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	204.48	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	28.81	483.98	127.96	1,245.50	384.30
Gross Profit	154.76	942.44	393.22	1,343.60	347.62
Operating Expenses	194.80	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-19.13	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-20.42	203.83	-192.83	350.40	52.15
Provision for Tax	0.96	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-21.26	160.59	-188.05	222.40	41.54
Minority Interest	-0.23	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	7.97	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	-0.23	0.00	0.00	0.00	0.00
Non-Current Liabilities	5.32	210.18	135.71	2,116.80	705.49
Current Liabilities	46.61	233.78	102.33	961.30	132.66
Total Liabilities	70.41	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	17.81	630.60	404.74	7,231.50	1,749.63
Current Assets	42.08	1,344.12	515.78	3,020.50	1,200.55
Total Assets	70.41	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	6.02	212.71	102.84	1,203.70	690.94
Net Current Assets	-4.52	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	8.28	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	6.91	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-13.41	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-28.95	11.76	-22.53	8.98	1.79
ROE (%)	-138.09	10.86	-28.10	3.04	1.97
ROA (%)	-17.45	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-6.39	13.63	-30.58	-5.99	9.87
Net Margin (%)	-10.40	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-16.69	17.55	41.55	1.37	16.49
EBIT Growth (%)	-874.10	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-289.78	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-247.02	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	515.24	17.33	-12.65	2.19	2.16

Valuation Ratios

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-22.44	68.93	-34.59	--	189.42
Price / Book Value	6.89	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-85.05	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.09	0.01	0.00	0.06	0.01
Current Ratio	0.90	5.75	5.04	3.14	9.05
Quick Ratio	0.84	3.86	4.46	2.33	7.64
Interest Coverage	-35.76	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	LifeMD (LFMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	5.62	12.65	22.67	17.06	20.09
Asset Turnover	1.68	0.74	0.59	0.24	0.26
Receivable days	16.49	46.54	60.95	65.39	72.41
Inventory Days	25.89	331.92	193.84	221.09	146.53
Payable days	140.17	26.16	60.19	37.02	29.05
Cash Conversion Cycle	-97.78	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly